Examining acquired brain injury-associated symptoms and fluid-based biomarkers in females surviving intimate partner...

Acquired brain injury (ABI), including traumatic brain injury and hypoxic/anoxic injury, presents significant public health concerns; however, existing literature has focused primarily on male populations, such as military personnel and contact sports participants. Sex-related differences in ABI outcomes necessitate focused research due to potential heightened risk and distinct physiological responses among females.

This pilot study aims to explore fluid-based biomarkers for neurological injury and inflammation in females experiencing intimate partner violence (IPV)-related assaults to the head, neck, or face. It seeks to assess the feasibility and acceptability of non-invasive sweat patch collection for biomarker analysis and its association with post-injury symptoms.

This study will be a prospective longitudinal observational pilot study involving approximately 50 participants recruited from two mid-Atlantic-based hospital emergency departments.

Participants will undergo clinical interviews, provide blood and sweat samples, and complete questionnaires assessing ABI history, IPV-related symptoms, cognitive function, psychological well-being, and sweat patch acceptability, across three study visits. Screening procedures will identify eligible participants, followed by consent procedures, biosample collection, brain injury and IPV history survey administration, symptom and cognitive function instrument administration, and acute medical record data collection. Analyses will include random effects regression, product moment correlations, and descriptive statistics.

Participants will be informed about the study's purpose, procedures, and potential risks before providing consent. Compensation will be provided for participation, with withdrawal options available. Ethical considerations include ensuring participant confidentiality and addressing psychological disorders beyond exclusion criteria.

Understanding fluid-based biomarkers in IPV-related ABI can inform interdisciplinary interventions and precision care models. Findings may facilitate early detection, treatment, and safety planning for affected females, emphasizing the importance of tailored, accessible care for this vulnerable population. Future research should focus on translating these findings into evidence-based practice to improve outcomes for women with ABI, particularly those resulting from IPV.